Supply chain management in the drug industry
Subtitle: delivering patient value for pharmaceuticals and biologics
By: Hedley Rees
Publisher: Wiley
Published: 2011
Place of publication: Hoboken, N.J
Language: eng
Number of pages: 432
ISBN-13: 9780470555170
Subjects: Pharmaceutical industry; Drug Industry; Organization & administration; Materials management
Description: "This book bridges the gap between practitioners of supply-chain management and pharmaceutical industry experts. It aims to help both these groups understand the different worlds they live in and how to jointly contribute to meaningful improvements in supply-chains within the globally important pharmaceutical sector. Scientific and technical staff must work closely with supply-chain practitioners and other relevant parties to help secure responsive, cost effective and risk mitigated supply chains to compete on a world stage. This should not wait until a drug has been registered, but should start as early as possible in the development process and before registration or clinical trials"--Provided by publisher.
Notes: Includes bibliographical references and index.
Table of contents: title: Machine generated contents note: PART I: SURVEYING AND MAPPING THE TERRITORY.; title: CHAPTER 1 SETTING A TRANSFORMATIONAL AGENDA.; title: 1.1 Aims and aspirations of the book.; title: 1.2 Book Format.; title: 1.3 Intended readership.; title: 1.4 A book about two worlds in contrast.; title: 1.5 The pharmaceutical lottery.; title: 1.6 Supply Chain Management (SCM) in context.; title: 1.7 The History of Supply and Value Generation.; title: 1.8 The Development of Processes to Manage the Supply Chain.; title: 1.9 Life in SCM.; title: 1.10 Moving forward.; title: CHAPTER 2 PLOTTING A COURSE TO PATIENT VALUE.; title: 2.1 Why focus on Patient Value?; title: 2.2 Where does the patient currently fit?; title: 2.3 Why is it necessary to plot a course?; title: 2.4 Understanding how the course is presently set.; title: 2.5 Capturing value for patients.; title: CHAPTER 3 PHARMACEUTICAL DRUG DEVELOPMENT.; title: 3.1 Drug development's role in the supply chain.; title: 3.2 Introduction to drug development.; title: 3.3 The Medicinal Product.; title: 3.4 Clinical Trials.; title: 3.5 Related Development Programmes.; title: 3.6 Managing Clinical Programs.; title: 3.7 Regulatory Affairs and Authorities.; title: 3.8 Supply Chain Management in Development Programmes.; title: 3.9 Manufacture and Supply of Commercial Product.; title: 3.10 Supply Chain Management for Commercial Product.; title: CHAPTER 4 END-TO-END PHARMACEUTICAL SUPPLY CHAINS.; title: 4.1 Where does responsibility for the supply chain lay?; title: 4.2 Sponsor companies, license holders and their supply chains.; title: 4.3 Supply chains for small molecule products.; title: 4.4 Starting at the final destination.; title: 4.5 How do drugs enter the body?; title: 4.6 Design of drug delivery systems.; title: 4.7 What does this mean for the supply chain?; title: 4.8 Key aspects of GMP/GDP in relation to SCM.; title: 4.9 An overview of the stages on route to patient delivery.; title: 4.10 Manufacture and supply of biological entities.; title: CHAPTER 5: WHY PHARMA SUPPLY CHAINS DON'T PERFORM.; title: 5.1 Supply chain underperformance.; title: 5.2 Is there a case to answer?; title: 5.3 Birth to infancy - the supply chain critical stage.; title: 5.4 Commercial supply under the patent protection umbrella.; title: 5.4.1 Limited competitive alternatives.; title: 5.4.2 Fragmentation.; title: 5.4.3 Supplier power.; title: 5.4.4 The position of those buying pharmaceutical products.; title: 5.5 What does this mean for the pharmaceutical supply chain?; title: PART II: BUILDING A KNOWLEDGE FOUNDATION IN SCM.; title: CHAPTER 6 SUPPLY CHAIN MANAGEMENT AS A COMPETETIVE WEAPON.; title: 6.1 Competition and business strategy.; title: 6.2 The marketing mix.; title: 6.3 Porter's Five Forces.; title: 6.4 Porter's Generic Competitive Strategies.; title: 6.5 Porters Value Chain.; title: 6.6 Competitive strategy and customers.; title: 6.7 The Japanese Experience.; title: 6.8 Total Quality Management.; title: 6.9 Lean Thinking.; title: 6.10 Focusing on value for money.; title: 6.11 SCM processes in competitive strategy.; title: 6.12 SCM in biotech/virtual companies.; title: 6.13 Competition in pharmaceuticals.; title: CHAPTER 7 SUPPLY CHAIN MANAGEMENT (SCM) HOLISTIC.; title: 7.1 The relevance of SCM to Pharmaceuticals.; title: 7.2 Production systems and the holistic of SCM.; title: 7.3 The Core of SCM.; title: 7.4 First principle of SCM.; title: 7.5 Supply chains as a series of interconnected systems.; title: 7.6 Processes to manage the supply chain.; title: 7.7 A word about processes.; title: 7.8 How the SCM processes should mesh together.; title: 7.9 Production & Inventory Control (P & IC).; title: 7.10 Strategic Procurement.; title: 7.11 Transportation, storage and distribution.; title: 7.12 Information Systems and Technology (IS/IT).; title: 7.13 Improvement.; title: CHAPTER 8 PRODUCTION & INVENTORY CONTROL (P & IC).; title: 8.1 Core mission.; title: 8.2 First principles of production and inventory control (P & I C).; title: 8.3 The Wholesome Trinity (TWT) in P & IC.; title: 8.4 The Wholesome Trinity (TWT) and customer expectations.; title: 8.5 Leveraging 'The Wholesome Trinity' (TWT).; title: 8.6 The impact of variety on supply chains.; title: 8.7 Designing appropriate production systems.; title: CHAPTER 9 STRATEGIC PROCUREMENT.; title: 9.1 Core mission.; title: 9.2 The Purchasing Portfolio.; title: 9.3 The Process of Procurement.; title: 9.4 Strategic sourcing and planning.; title: 9.5 Outsourcing.; title: 9.6 Basic principles in contracting for supply.; title: 9.7 Finally, a typical organisational tension over procurement.; title: CHAPTER 10 TRANSPORTATION, STORAGE AND DISTRIBUTION.; title: 10.1 Defining the core mission.; title: 10.2 International trade and commerce.; title: 10.3 The World Trade Organization (WTO).; title: 10.4 Intermediary arrangements.; title: 10.5 Terms of Trade - Incoterms 2000.; title: 10.6 Ownership of goods (Title).; title: 10.7 Third Party Logistics (3PL) Providers.; title: 10.8 Customs.; title: 10.9 Shipping regulations relating to materials.; title: 10.10 A finishing note.; title: CHAPTER 11 INFORMATION SYSTEMS (IS) and INFORMATION TECHNOLOGY (IT).; title: 11.1 Overview.; title: 11.2 A brief (layman's - and very brief!) history of computer systems development.; title: 11.3 IS/IT and Business Process Management (BPM) - Dee Carrie.; title: 11.4 IS/IT and Supply Chain Management.; title: 11.5 IS/IT and patient safety - Adrian Hampshire.; title: 11.6 IS/IT and the regulations.; title: 11.7 IS/IT and SOPs.; title: CHAPTER 12 IMPROVEMENT.; title: 12.1 Why improve?; title: 12.2 Improvement and Production Systems.; title: 12.3 The improvement journey.; title: CHAPTER 13 BRINGING THE HOLISTIC TOGETHER.; title: 13.1 Setting the scene.; title: 13.2 The process explained.; title: 13.3 Developing an action agenda.; title: 13.4 An illustrative case study.; title: PART III: PLANNING AND EXECUTING SUPPLY CHAIN CHANGE.; title: CHAPTER 14 IMPROVEMENT IN PHARMACEUTICALS.; title: 14.1 Where are we now?; title: 14.2 Subsequent developments since inception.; title: 14.3 A Blueprint for Quality by Design (QbD).; title: CHAPTER 15 EXEMPLAR THINKING IN ORGANISATIONAL IMPROVEMENT.; title: 15.1 Where are we now?; title: 15.2 What is meant by 'Exemplar'?; title: 15.3 A dialogue on exemplar improvement.; title: CHAPTER 16 BUILDING A FOUNDATION FOR SUSTAINABLE CHANGE.; title: 16.1 Focus on the individual.; title: 16.2 Individuals as leaders.; title: 16.3 Individuals as motivators and the motivated.; title: 16.4 Individuals as group members.; title: 16.5 Individuals as participants in cultural change.; title: 16.6 CASE STUDY MILES LTD., BRIDGEND, GLAMORGAN.; title: CHAPTER 17 A CURE FOR THE PHARMACETICAL SUPPLY CHAIN.; title: 17.1 What is the disease state?; title: 17.2 What is the label claim for the Medicine?; title: 17.3 What will life hold without the medicine?; title: 17.4 What is this 'better way' to develop drugs?; title: 17.5 Full scale production of drugs.; title: 17.6 What are the barriers to change?; title: 17.7 What are the potential benefits of change?; title: 17.8 Defining the art of the possible.; title: 17.9 Concluding message.